Cannabidiol for drug resistant epilepsy

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Apr 2023: Trial registered, NCT05803434
  2. 14 Mar 2024: Trial started, NCT05803434

The trials

NCT05803434: Cannabidiol in Children and Young Adults With Rare Disease-associated Severe Epilepsy

State
Under way
Phase
Phase 2
People
30 planned
Started
14 Mar 2024
Primary completion
1 Apr 2026
Arms
Cannabidiol treatment
Results
None posted
  1. 7 Apr 2023: Trial registered
  2. 14 Mar 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Cardiolrx, Canapure PH, Cannabidiol (Epidiolex), Cannabidiol Oral Solution, Epidiolex, Epidiolex 100 mg/mL Oral Solution, Epidyolex, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose, GWP42003-P 5 mg/kg/day Dose, MediCabilis.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.